Clinical Trial TitleA phase Ib trial of neoadjuvant AMG 232 concurrent with preoperative radiotherapy in wild-type P53 soft tissue sarcoma (STS).
Clinical Trial Protocol Description:
This phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Have pathologically proven diagnosis of grade 2-3 (intermediate or high grade) soft tissue sarcoma.
- Have a planned definitive surgical resection of the primary tumor.
- Have an Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status of 0-1 within 30 days prior to registration.
This is a partial list of inclusion and exclusion criteria.